| Literature DB >> 31684959 |
Andrés Cruz-Herranz1, Michael Dietrich2, Alexander M Hilla3, Hao H Yiu1, Marc H Levin4,5, Christina Hecker2, Andrea Issberner2, Angelika Hallenberger6, Christian Cordano1, Klaus Lehmann-Horn7, Lisanne J Balk8, Orhan Aktas2, Jens Ingwersen2, Charlotte von Gall6, Hans-Peter Hartung2, Scott S Zamvil1,9, Dietmar Fischer3, Philipp Albrecht10, Ari J Green11,12.
Abstract
BACKGROUND: Retinal optical coherence tomography (OCT) is a clinical and research tool in multiple sclerosis, where it has shown significant retinal nerve fiber (RNFL) and ganglion cell (RGC) layer thinning, while postmortem studies have reported RGC loss. Although retinal pathology in experimental autoimmune encephalomyelitis (EAE) has been described, comparative OCT studies among EAE models are scarce. Furthermore, the best practices for the implementation of OCT in the EAE lab, especially with afoveate animals like rodents, remain undefined. We aimed to describe the dynamics of retinal injury in different mouse EAE models and outline the optimal experimental conditions, scan protocols, and analysis methods, comparing these to histology to confirm the pathological underpinnings.Entities:
Keywords: Experimental autoimmune encephalomyelitis; Experimental optic neuritis; Multiple sclerosis; Neurodegeneration; Optical coherence tomography; Optokinetic response
Mesh:
Year: 2019 PMID: 31684959 PMCID: PMC6827223 DOI: 10.1186/s12974-019-1583-4
Source DB: PubMed Journal: J Neuroinflammation ISSN: 1742-2094 Impact factor: 8.322
Fig. 1a–c Fundus image of mouse retina with segmentation of OCT, where each green line depicts a B-scan. a Volume scan taken from raster scan of the optic nerve head. Area in blue includes the region of calculated volume. b Peripapillary ring and c horizontal and vertical line scans. d–f Examples of B-scans obtained from volume (d), peripapillary ring (e), and (f) line scans. On the right half of each B-scan, the results of the semi-automated segmentation of the layers are shown with retinal layers labeled. g Horizontal B-scan in a SJL/J mouse, with atrophy of outer retinal layers, a characteristic finding in retinal degeneration 1. h Schematic representation of a retina dissected from an eyeball (left) and a whole mount for histological analysis (right). The dotted line represents cuts made on the retina; the red squares represent areas analyzed in the central (1), mid-peripheral (2), and far-peripheral retina (3)
EAE clinical severity scores
| 0 | No signs of disease. |
| 0.5 | Mild tail paresis: tip of the tail is weak and/or mouse does not spin tail. |
| 1 | Obvious tail paresis or plegia. |
| 1.5 | When flipped on its back, the mouse does not turn instantly in |
| 2 | Mild signs of hind limb paresis, like abnormal or slow gait, abnormal posture of the posterior part of the body. |
| 2.5 | Obvious signs of hind limb paresis, like abnormal, slow, and weak movements of one or both hind limbs. |
| 3 | Signs of hind limb plegia: drags one hind limb behind (if the limb is moved a little but it does not help the mouse to move, this will count as a 3). |
| 3.5 | Signs of hind limb plegia: drags both hind limbs behind (if the limbs are moved a little but it does not help the mouse to move, this will count as a 3.5). |
| 4 | Mild signs of quadriparesis (weakness of all 4 limbs), as described in 2–3.5 and signs of weakness of one or both front limbs, like reduced speed when pulling itself forward, inability to push its chest up from ground, or reduced ability (shorter duration) to hold itself up against gravity on the edge of the cage. |
| 4.5 | Quadriplegia: cannot or barely pull itself forward or hold itself on the edge of the cage (in this stage the mouse has to be monitored closely and has to be sacrificed before 24 h if the condition does not improve). |
| 5 | Mouse found dead. |
List of antibodies used for immunofluorescence microscopy
| Type | Manufacturer | Catalog # | Host species | Dilution used | |
|---|---|---|---|---|---|
| Primary antibodies | Anti-CD3 | Dako, Hamburg, Germany | A0452 | Mouse | 1:400 |
| Anti-Iba1 | Wako, Richmond, VA, USA | 019-19741 | Rabbit | 1:500 | |
| Anti-MBP | Millipore, Burlington, MA, USA | MAB386 | Rat | 1:500 | |
| Anti-Brn3a | Santa Cruz Biotechnology, Dallas, TX, USA | sc-31984 | Goat | 1:200 | |
| Anti-βIII-tubulin | Biolegend, San Diego, CA, USA | 801201 | Mouse | 1:1000 | |
| Seconday antibodies | Alexa Fluor-555 Anti-Goat | Life Technologies, Carlsbad, CA, USA | A-21432 | Donkey | 1:200 |
| Alexa Fluor-488 Anti-Rabbit | Life Technologies, Carlsbad, CA, USA | A-21206 | Donkey | 1:200 | |
| Cy3 anti-Rabbit | Millipore, Burlington, MA, USA | AP187c | Goat | 1:500 | |
| Cy3 anti-Mouse | Millipore, Burlington, MA, USA | AP124c | Goat | 1:500 | |
| Cy3 anti-Rat | Millipore, Burlington, MA, USA | AP183C | Goat | 1:500 |
Summary of EAE experiments and results
| Figures | Strain | Encephalytogenic peptide | OCT follow-up period | OCT time points (months after immunization) | OCT findings | Histological findings | Additional findings |
|---|---|---|---|---|---|---|---|
| 2, 3, 4, 6 | WT C57Bl/6J | MOG35–55 | 120 days | 0, 0.5, 1, 2, 3, 4 | Initial IRL swelling mirroring EAE onset and peak, followed by progressive thinning | Optic neuritis (T cell infiltration, microglial activation, and demyelination) with 32% RGC loss. Decrease of myelinated nerve fibers and destruction of the myelin structure. | Decreased visual acuity (OKR) |
| 2, 3 | WT C57Bl/6J | MBP | 120 days | 0, 0.5, 1, 2, 3, 4 | No change | No optic neuritis or RGC loss | |
| 2, 3 | TCR2D2 | MOG35–55 | 120 days | 0, 0.5, 1, 2, 3, 4 | IRL atrophy already present at 2 weeks | Severe optic neuritis with 49% RGC loss | |
| 5 | WT C57Bl/6J | MOG35–55 | 9 months | 0, 1, 2, 5, 7, 9 | Progressive IRL and INL thinning, more pronounced during the first 2 months | 54% RGC loss | |
| 6 | SJL/J | PLP139–151 | 7 months | 0, 1, 2, 5, 7 | Progressive IRL atrophy, also present to a lesser degree in sham-immunized mice |
Fig. 2a Clinical EAE score of C57Bl/6J mice immunized with MOG or MBP peptide, as well as TCR2D2 transgenic mice immunized with MOG peptide. b Change of the inner retinal layers of TCRWT and TCR2D2 mice. c IRL change of C57BL/6J mice immunized with MBP. d Retinal wholemounts stained by βIII-tubulin antibody from groups indicated in a. The representative images display the most severe disease progression. e The bar graph shows the RGC density 120 days after immunization. Time courses and bar graphs represent the pooled mean ± SEM of two separate EAE experiments each with at least four animals per group, *P > 0.05; **P < 0.01; ***P < 0.001; time courses (area under the curve) were compared to sham, and bar graph compared to sham TCRWT mice by ANOVA with Dunnett’s post hoc test
Fig. 3a Optic nerves of mice 120 days after MOG or MBP immunization stained by H&E and CD3, Iba1, or MBP antibodies. Optic nerves were compared by an established infiltration score according to H&E staining (b) (Shindler et al. [3]), MBP score for the myelin status (c), Iba1 fluorescence intensity measurement for microglia activation (d), and CD3+ cell infiltration (e). The bar graphs represent the pooled mean ± standard deviation of at least two separate EAE experiments each with at least four animals per group; one optic nerve per mouse was included, *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant, by ANOVA with Dunnett’s post hoc test compared to sham-treated mice
Fig. 4a Electron microscopy images of longitudinal sections of the optic nerve fibers from sham- and MOG35–55-treated C57Bl/6J wild-type mice. b The myelin-axon ratio was determined by the thickness of the myelin sheath and the axon. Bar graphs represent the pooled mean ± SD of an EAE experiment with four animals per group; **P < 0.01 two-tailed Student’s t test compared to sham-treated mice
Fig. 5MOG35–55 EAE in C57Bl/6J (n = 17) vs. sham-immunized (n = 12) mice. a EAE clinical scores. b Decreased visual acuity of EAE mice compared to untreated C57Bl/6J mice. OKR measurement was carried out for 120 days after MOG immunization as described above, area under the curve compared by ANOVA with Dunnett’s post hoc test. c–f Thickness of retinal layers. h–l RGC count after 9 months. Data expressed as mean ± SEM, *P < 0.05; **P < 0.01; ***P < 0.001. P values for OCT and RGC data obtained from generalized estimating equation models accounting for within-mouse, inter-eye correlations. m–r Linear regression analyses. IRL thickness during EAE is associated with ultimate neuronal loss (top row) and disease severity (bottom row). Similar results were obtained 5 and 7 months after immunization (data not shown). ß, generalized estimating equation association coefficient
Fig. 6a Clinical EAE scores in PLP139–151 EAE in SJL mice. The abscissa axis represents days after immunization. b IRL thickness in PLP139–151 EAE (n = 10) vs. sham-immunized (n = 5) SJL/J mice. Data expressed as mean ± SEM; *P < 0.05; **P < 0.01